Cargando…

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin-Broto, Javier, Redondo, Andres, Moura, David S., Valverde, Claudia, Morales, Jose Manuel, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Gutierrez, Antonio, Díaz-Beveridge, Roberto, Luna, Pablo, Martinez-Marin, Virginia, Marcilla, David, Arribas, Ivan, Ledesma, Patricio, Lopez-Martin, Jose Antonio, Di Lernia, Davide, Zamora, Jorge, Hindi, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587294/ https://www.ncbi.nlm.nih.gov/pubmed/36271011 http://dx.doi.org/10.1038/s41467-022-33975-6

Ejemplares similares

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
por: Redondo, Andrés, et al.
Publicado: (2017)

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
por: Martin-Broto, Javier, et al.
Publicado: (2020)

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)
por: López-Pousa, A., et al.
Publicado: (2016)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
por: Hidalgo-Ríos, Samuel, et al.
Publicado: (2022)

A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
por: Martínez-Trufero, Javier, et al.
Publicado: (2021)

Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus
por: Álvarez Álvarez, Rosa, et al.
Publicado: (2019)

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study
por: Maurel, Joan, et al.
Publicado: (2016)

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)
por: Poveda, Andrés, et al.
Publicado: (2014)

Sequential therapy with induction chemotherapy and chemoradiotherapy in pre-irradiated recurrent head and neck squamous cell carcinoma incorporating nab-paclitaxel—a commentary of the phase I trial of AFHX followed by concomitant FHX scheme
por: Martinez-Trufero, Javier, et al.
Publicado: (2023)

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients
por: Moura, David S., et al.
Publicado: (2018)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
por: Martin-Broto, Javier, et al.
Publicado: (2023)

A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
por: Martin-Broto, Javier, et al.
Publicado: (2021)

2023 GEIS Guidelines for gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2023)

Percutaneous Microwave Ablation of Desmoid Fibromatosis
por: Martínez-Martínez, Alberto, et al.
Publicado: (2021)

Evaluation of NAB2-STAT6 Fusion Variants and Other Molecular Alterations as Prognostic Biomarkers in a Case Series of 83 Solitary Fibrous Tumors
por: Salguero-Aranda, Carmen, et al.
Publicado: (2021)

Giant cell tumour of bone: new treatments in development
por: López-Pousa, A., et al.
Publicado: (2015)

Reduction of Tumor Growth with RNA-Targeting Treatment of the NAB2–STAT6 Fusion Transcript in Solitary Fibrous Tumor Models
por: Li, Yi, et al.
Publicado: (2023)

Desmoid-Type Fibromatosis
por: Garcia-Ortega, Dorian Yarih, et al.
Publicado: (2020)

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)
por: Mora, J, et al.
Publicado: (2017)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
por: Hindi, Nadia, et al.
Publicado: (2020)

Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740
por: Hindi, Nadia, et al.
Publicado: (2021)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
por: Martínez‐Trufero, Javier
Publicado: (2022)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin
por: Moura, David S., et al.
Publicado: (2021)

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
por: Fernandez-Serra, Antonio, et al.
Publicado: (2020)

Changes in crevicular cytokines after application of melatonin in patients with periodontal disease
por: Montero, Javier, et al.
Publicado: (2017)

Cancer Stem Cells in Soft-Tissue Sarcomas
por: Martínez-Delgado, Paula, et al.
Publicado: (2020)

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
por: Serrano, César, et al.
Publicado: (2020)

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
por: Moura, David S., et al.
Publicado: (2020)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
por: Gronchi, Alessandro, et al.
Publicado: (2019)

Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
por: Napolitano, Andrea, et al.
Publicado: (2020)

The Unknown Process Osseointegration
por: López-Valverde, Nansi, et al.
Publicado: (2020)

Electromyographic and patient-reported outcomes of a computer-guided occlusal adjustment performed on patients suffering from chronic myofascial pain
por: Dib, Abraham, et al.
Publicado: (2015)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
por: Alvarez, R, et al.
Publicado: (2014)

SEOM clinical guideline in nasopharynx cancer (2017)
por: Pastor, M., et al.
Publicado: (2017)

Extra-Abdominal Desmoid Tumor Located in the Axilla
por: Pacheco Compaña, Francisco Javier, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9t2btn5bh06hcbtuhml415f69u